Possible biological mechanisms of entecavir versus tenofovir disoproxil fumarate on reducing the risk of hepatocellular carcinoma

Abstract

AbstractHepatitis B virus (HBV) is a life‐threatening infectious virus associated with the risk of liver failure and hepatocellular carcinoma (HCC). Regarding HBV treatment, the recent development of nucleoside/nucleotide analogs (NUC), HBV reverse transcriptase inhibitors, enabled favorable viral control as well as improved prognosis in patients with chronic hepatitis B. However, NUC fails to clear HBV because the formation of covalently closed circular DNA or HBV surface antigen occurs upstream of the point of action of NUC. Recently, we found that acyclic nucleoside phosphonates (ANP) such as adefovir or tenofovir, but not lamivudine or entecavir, induced IFN‐λ3 productions in the gastrointestinal tract and modulated lipopolysaccharide (LPS)‐mediated cytokine profiles in peripheral blood mononuclear cells, such as interleukin (IL)‐12p70 induction and IL‐10 inhibition, which are immunologically favorable cytokine profiles for HBV elimination. Furthermore, IFN‐α, in combination with ANP, showed additional and synergistic effects on IFN‐λ3 and IL‐12p70 production, respectively, while not affecting IL‐10 levels. Mechanistic analyses of the cytokine modulation by ANP revealed that ANP blocked the mammalian target of the rapamycin (mTOR) pathway by inhibiting Akt translocation to the plasma membrane, thereby inhibiting Akt phosphorylation. As it has been reported that IFN‐λ inhibits tumor growth directly or indirectly and the mTOR pathway is generally activated in most cancer cells, ANP might have potential anti‐HCC effects. Our in vitro and ex vivo findings might stir the debate on whether types of NUC affect the risk of HBV‐related HCC incidence.